NEW YORK (GenomeWeb News) – Affymetrix will pay $73 million in cash to acquire Panomics, a maker of assays for low- to mid-plex genetic, protein, and cellular analysis applications, Affy said today.
 
Affymetrix said that the acquisition will strengthen its position in the high-growth validation and routine testing markets, and it will enable it to offer a more complete customer workflow that will combine Affy’s whole-genome microarray products with Panomics’ products focused on genes and proteins of interest.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

The Wall Street Journal looks into the cost of new gene therapies.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.

Oct
17
Sponsored by
Lexogen

This webinar will present a method for RNA-seq expression analysis of FFPE-derived RNA samples that are too degraded for successful application of standard RNA-seq techniques.

Oct
25
Sponsored by
Roche

This webinar will detail a comprehensive strategy that a lab has put in place to evaluate  NGS oncology assays for genomic tumor profiling of plasma and tissue samples.